The
Food and Drug Administration (FDA) has approved a groundbreaking trial
to evaluate the safety of using a child’s own cord-blood stem cells to
regenerate cells in the inner ear—and potentially restore the child’s
hearing. The year-long Phase 1 study, which began on Jan. 10, will
follow 10 children who have a moderate to profound unilateral or
bilateral hearing loss.